Post-menopausal women who engage in moderate to vigorous exercise have a reduced risk of breast cancer. This comes from researchers writing the open access journal BMC Cancer who investigated the link between breast cancer and exercise. "With an estimated 182, 460 new cases diagnosed in the United States in 2008, breast cancer is recognized as the most common cancer affecting U.S. women" says Dr. Tricia M Peters from the U.S. National Cancer Institute, Bethesda, Maryland, who headed up an international team of researchers. Vigorous exercise has been hypothesized to reduce cancer risk for some time. However, this new study is one of the first prospective investigations to look at the importance of various intensities of exercise at different stages in an individual's life. Over 110, 000 post menopausal women were asked to rate their level of physical activity at ages 15-18, 19-29, 35-39, and in the past 10 years. It was found, over 6.6 years of follow up, that women who engaged in more than 7 hours per week of moderate-to-vigorous exercise for the last ten years were 16% less likely to develop breast cancer than those who were inactive.
Michael Holick, PhD, MD, director of the Bone Healthcare Clinic and the Vitamin D, Skin and Bone Research Laboratory at Boston University School of Medicine BUSM recently received the 2009 NAMS/Upsher-Smith Laboratories, Inc.Vitamin D Research Award from the North American Menopause Society (NAMS). Holick was presented with the award during NAMS' 20th annual meeting in San Diego, California on September 30 - October 3, 2009. NAMS/Upsher-Smith Laboratories, Inc. Vitamin D Research Award recognizes an individual whose body of research has advanced the understanding of the role of vitamin D-either endogenous or exogenous-for peri-and postmenopausal women. "These NAMS awards represent the Society's commitment to enhancing women's health. In honoring outstanding researchers, health professionals, and the media, the Society strongly confirms its role in stimulating and acknowledging quality research and health care, " said NAMS Executive Director Wulf H. Utian, MD, PhD, DSc (Med), NCMP.
SE5-OH containing Natural S-equol, a novel soy germ-based ingredient in a supplement, improved menopausal symptoms, including significantly reducing hot flash frequency by nearly 59 percent, according to a peer-reviewed study in Japanese women. This key study was presented in an oral presentation at the North American Menopause Society (NAMS) 20th annual meeting. A second oral presentation reported peer-reviewed data that documented for the first time the pharmacokinetics, or absorption and distribution in the body, in U.S. menopausal women of S-equol when taken as a supplement using SE5-OH containing Natural S-equol. Development and ongoing research of SE5-OH containing Natural S-equol is conducted by the Saga Nutraceuticals Research Institute of Otsuka Pharmaceutical Co., Ltd. Pharmavite LLC, the makers of NatureMade® vitamins and minerals and a subsidiary of Otsuka Pharmaceutical Co., Ltd., is studying SE5-OH containing Natural S-equol in supplement form for management of menopausal symptoms.
Women who developed new-onset breast tenderness after starting estrogen plus progestin hormone replacement therapy were at significantly higher risk for developing breast cancer than women on the combination therapy who didn't experience such tenderness, according to a new UCLA study. The research, published in the Oct. 12 issue of the Archives of Internal Medicine, is based on data from more than 16, 000 participants in the Women's Health Initiative estrogen-plus- progestin clinical trial. This trial was abruptly halted in July 2002 when researchers found that healthy menopausal women on the combination therapy had an elevated risk for invasive breast cancer. Researchers do not know why breast tenderness indicates increased cancer risk among women on the combination therapy, said the new study's lead researcher, Dr. Carolyn J. Crandall, a clinical professor of general internal medicine and health services research at the David Geffen School of Medicine at UCLA. "Is it because the hormone therapy is causing breast-tissue cells to multiply more rapidly, which causes breast tenderness and at the same time indicates increased cancer risk?
Earlier this year, the BBC reported that "HRT - Hormone Replacement Therapy - can shrink women's brains"1, after a study was published which showed that brain volume in women taking HRT was smaller in two key areas involved in thinking and memory. This comes in addition to earlier results from the Women's Health Initiative (WHI) Memory Study2 that linked HRT to an increased risk of memory loss and dementia, and an article in the Lancet3 which concluded that HRT "substantially increases the risk of dementia of any cause and cognitive* decline" (* memory, thinking and understanding). This adds to the growing body of evidence that the risks of HRT far outweigh any perceived benefits, evidence that Nutri Pharma feels needs to be brought to the attention of the 150, 000 women in Norway and millions of women across Europe who are still being prescribed this treatment. Nutri5® is Nutri Pharma's natural product for the relief of menopausal symptoms, shown to be effective in an open pilot study.
Depomed Reports Results From Two Phase 3 Clinical Trials Evaluating Non-Hormonal Therapy For Menopausal Hot Flashes
Depomed, Inc. (NASDAQ:DEPO) announced top-line results from the BREEZE 1 and 2 Phase 3 clinical trials evaluating the safety and efficacy of SeradaTM, an investigational non-hormonal extended release formulation of gabapentin for the treatment of menopausal hot flashes. In the higher dose treatment arm of the two doses evaluated, the 1800mg dose achieved positive results at 4 weeks. All four co-primary endpoints of the 1800mg dose at 4 weeks demonstrated significant reductions in frequency and severity in both clinical trials (p-values ranged from 0.0001 to 0.004). Of the other four co-primary endpoints of the 1800mg dose at 12 weeks, one endpoint was positive (p=0.0026) while the other three endpoints did not achieve statistical significance. In the lower dose treatment arm, the 1200mg dose at 4 weeks achieved statistical significance in three of the four co-primary endpoints. Frequency was significantly reduced in both clinical trials (p-values of 0.0024 and 0.0117) at four weeks.
The right combination of estrogen and a selective estrogen receptor modulator (SERM), which blocks the effects of estrogen in breast tissue, could relieve menopause symptoms and cut breast cancer risk, Yale researchers report in an abstract presented at the American Society for Reproductive Medicine (ASRM) scientific meeting in Atlanta, Georgia, October 17-21. Women in menopause who have symptoms, but have not had a hysterectomy are currently treated with a combination of estrogen plus progestin hormone therapy, but this treatment comes with side effects, including a higher risk of breast cancer caused by the progestin. To find a better way of administering hormone therapy without the breast cancer risk, Hugh S. Taylor, M.D., professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale, and his colleagues treated breast and endometrial cell lines with either estrogen or estrogen plus one of the SERMs. The team then looked at various markers of cell growth, including proliferating cell nuclear antigen (PCNA), one of the best-characterized markers of cell growth.
Hormone replacement therapy (HRT) to treat menopausal estrogen deficiency has been in widespread use for over 60 years. Several observational studies over the years showed that HRT use by younger postmenopausal women was associated with a significant reduction in total mortality; available evidence supported the routine use of HRT to increase longevity in postmenopausal women. However, the 2002 publication of a major study, the Women's Health Initiative (WHI), indicated increased risk for certain outcomes in older women, without increasing mortality. This sparked debate regarding potential benefits or harm of HRT. In an article published in the November 2009 issue of The American Journal of Medicine, researchers conducted a meta-analysis of the available data using Bayesian methods and concluded that HRT almost certainly decreases mortality in younger postmenopausal women. Bayesian analysis uses prior data, updated with new information, to make statistical inferences. The authors pooled results from 19 randomized trials that included age-specific data from the WHI, with 16, 000 younger postmenopausal women (mean age 55 years) followed for 83, 000 patient-years, and showed a mortality relative risk of 0.
For estrogen replacement to provide stroke protection, it likely must be given soon after levels drop because of menopause or surgical removal of the ovaries, scientists report in the Journal of Neuroscience. Animal studies indicate a "critical period" for estrogen replacement and that when therapy is delayed, estrogen receptors on brain cells are significantly diminished along with the neuroprotection estrogen typically conveys, according to scientists from the Medical College of Georgia, North China Coal Medical University and the University of Texas Health Sciences Center at San Antonio. "We looked at the controversy over whether estrogen is going to be beneficial after long periods without it and found the answer appears to be 'no, '" says Dr. Darrell W. Brann, chief of MCG's Developmental Neurobiology Program and the study's corresponding author. The controversy he's referencing resulted from the Women's Health Initiative, a 12-year study of 161, 808 women ages 50-79 that examined the health benefits of hormone replacement therapy.
The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer. "Postmenopausal hormone treatment is associated with increased rates of benign breast biopsies, and early and late stages of cancer. Atypical ductal hyperplasia is associated with the use of postmenopausal hormone treatment and its rates have decreased with the decline in use of this treatment, " said researcher Tehillah Menes, M.D., who was the chief of breast service in the Department of Surgery at Elmhurst Hospital Center, New York, when this study was conducted. Details of these findings are published in Cancer Epidemiology, Biomarkers & Prevention, which is a journal of the American Association for Cancer Research. Atypical ductal hyperplasia is abnormal cells that grow in the milk ducts of the breast. Previous research has shown that women who are diagnosed with atypical ductal hyperplasia are at a three- to five-fold increased risk of developing breast cancer.